Crown Bioscience 3D Ex Vivo Patient Tissue Platform

Crown Bioscience, a JSR Life Sciences company specializing in contract biopharmaceutical R&D, has launched its 3D Ex Vivo Patient Tissue Platform. Using freshly collected patient tumor material, this new service can accurately measure oncology and immuno-oncology drug-induced tumor killing and endogenous immune cell proliferation, the company said. The technology aims to improve clinical success rates by using the most patient-relevant tumor samples to better predict tumor response to potential drug candidates. The automated high-throughput platform uses high-content 3D imaging and image analysis to quantify distinct responses of individual cell populations in fresh patient tissues. These analyses can assess responses to different doses of therapeutic candidates at various timepoints and can determine the effects of the drug or combination of drugs on tumor killing and immune cell proliferation.